EREG enhances glycolysis through activating EGFR signaling and its downstream glycolytic genes in tamoxifen-resistant BCa cells, whereby EREG is a direct target of miR-186-3p, downregulation of which by tamoxifen causes EREG upregulation in these cancer cells [67]. This evidence concerns the gene EGFR and cancer.